Corrie Virtual Atrial Fibrillation Management Program for Atrial Fibrillation

Phase-Based Progress Estimates
Johns Hopkins University, Baltimore, MD
Atrial Fibrillation+1 More
Corrie Virtual Atrial Fibrillation Management Program - CombinationProduct
All Sexes
What conditions do you have?

Study Summary

The overall objective of this proposal is to evaluate the feasibility of a comprehensive digital atrial fibrillation (AFib) management tool that will empower patients to a) take an active role in learning about AFib management options, starting and adhering to evidence-based therapies and lifestyle changes and b) to guide the patients during AFib episodes which are associated with anxiety and impairment in quality of life. Researchers plan to evaluate the feasibility and preliminary efficacy of this novel digital toolkit in improving quality of life and decreasing AFib burden in a pilot randomized clinical trial (RCT).

Eligible Conditions

  • Atrial Fibrillation
  • Behaviour

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 14 Secondary · Reporting Duration: 12 weeks

12 weeks
Alcohol use as assessed by the Alcohol Use Disorders Identification Test
Anxiety as assessed by the Generalized Anxiety Disorder 7 score
Atrial Fibrillation Episode Burden
Atrial Fibrillation Severity as assessed by the Atrial Fibrillation Severity Scale
Blood pressure
Body Mass Index (BMI)
Depressive symptoms as assessed by the Patient Health Questionnaire 8
Diet as assessed by the Rate Your Plate (RYP) scale
Feasibility as assessed by the retention rate
Physical Activity as assessed by the Rapid Assessment of Physical Activity
Quality of life as assessed by the Atrial Fibrillation Effect on Quality-of-Life
Skills in applying electronic health information to health problems
Smoking status as assessed by study team developed questionnaire
Social Support as assessed by the Medical Outcomes Social Support Survey Instrument
Stress level as assessed by the Perceived Stress Score

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Usual Care
1 of 2
Corrie Virtual Atrial Fibrillation Management Program
1 of 2
Active Control
Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: Corrie Virtual Atrial Fibrillation Management Program · No Placebo Group · N/A

Corrie Virtual Atrial Fibrillation Management Program
Experimental Group · 1 Intervention: Corrie Virtual Atrial Fibrillation Management Program · Intervention Types: CombinationProduct
Usual CareNoIntervention Group · 1 Intervention: Usual Care · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks
Closest Location: Johns Hopkins University · Baltimore, MD
Photo of Johns Hopkins University 1Photo of Johns Hopkins University 2Photo of Johns Hopkins University 3
1997First Recorded Clinical Trial
5 TrialsResearching Atrial Fibrillation
692 CompletedClinical Trials

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,033 Previous Clinical Trials
30,782,275 Total Patients Enrolled
9 Trials studying Atrial Fibrillation
2,099 Patients Enrolled for Atrial Fibrillation
David Spragg, MDPrincipal InvestigatorJohns Hopkins University
2 Previous Clinical Trials
260 Total Patients Enrolled
2 Trials studying Atrial Fibrillation
260 Patients Enrolled for Atrial Fibrillation

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be at least 18 years old.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.